Trending...
- Assent Expands Executive Team to Accelerate Global Growth & Innovation
- The World's Largest Green Economic Revolution Emerges as Nature, Tech, and Finance Converge
- DivX Empowers Media Enthusiasts with Free Expert Guides for Advanced MP4 Management
LAS VEGAS, Aug. 6, 2020 /PRNewswire/ -- GVB Biopharma, a pharmaceutical company specializing in hemp and cannabis-related consumer products, announced today that it has established the process and infrastructure for producing medicinal products from cannabigerol (CBG). This natural cannabinoid is a critical precursor molecule to two well-known cannabinoids: tetrahydrocannabinol (THC) and cannabidiol (CBD).
With this venture, GVB Biopharma creates a scientific foundation and professional network for a research and development program for CBG, allowing for the rapid development of licensable intellectual property. In addition to CBG, this well-vetted process can be used to identify and develop other target molecules of interest.
The process will be established in two phases with two parts each. In the first phase, GVB will conduct extensive literature review of research on the endocannabinoid system and the effects of CBG, using the results to create an annotated database of scientific research. Next, GVB will oversee the chemical characterization of CBG, confirming the absence of pollutants and identifying important features like potency and shelf life.
More on nvtip.com
In the second phase, GVB Biopharma will create a biological characterization of CBG and assess its therapeutic potential and other meaningful uses. These efforts allow GVB to compile scientific evidence showing the value of CBG products to regulatory agencies, allowing for efficient access to the marketplace.
GVB Biopharma sets the industry standard for rigor in developing, testing and manufacturing hemp and cannabinoid products for the discerning consumer. With its state-of-the-art facilities for hemp processing in Oregon and white-label consumer product manufacturing in Nevada, GVB Biopharma sets the standard for product quality. From using rigorous research, to testing the genetic stability of seeds, to verifying the cannabinoid capacity of its plants and purity of the distilled oil, the integrity of the GVB Biopharma process is reflected in every product.
SOURCE GVB Biopharma
Related Links
www.gvbbiopharma.com
With this venture, GVB Biopharma creates a scientific foundation and professional network for a research and development program for CBG, allowing for the rapid development of licensable intellectual property. In addition to CBG, this well-vetted process can be used to identify and develop other target molecules of interest.
The process will be established in two phases with two parts each. In the first phase, GVB will conduct extensive literature review of research on the endocannabinoid system and the effects of CBG, using the results to create an annotated database of scientific research. Next, GVB will oversee the chemical characterization of CBG, confirming the absence of pollutants and identifying important features like potency and shelf life.
More on nvtip.com
- $10 Million Allocated to Establish Crypto Treasury Focused on High Value Ethereum (ETH) & Bitcoin (BTC) as Long-Term Holdings for Cybersecurity Leader
- Cummings Graduate Institute for Behavioral Health Studies Celebrates New DBH Graduates
- $100 to $200 Million Equity Agreement with Top Digital Advisor Bitwise to Power Major Digital Asset Initiative for Bitcoin and Solana: OFA Group
- New Collaboration Launches Corporate ESG Solution for Responsible Decommissioning and Transparent Reporting
- SlickCashLoan Launches Free Loan Calculator to Help You Plan Monthly Payments
In the second phase, GVB Biopharma will create a biological characterization of CBG and assess its therapeutic potential and other meaningful uses. These efforts allow GVB to compile scientific evidence showing the value of CBG products to regulatory agencies, allowing for efficient access to the marketplace.
GVB Biopharma sets the industry standard for rigor in developing, testing and manufacturing hemp and cannabinoid products for the discerning consumer. With its state-of-the-art facilities for hemp processing in Oregon and white-label consumer product manufacturing in Nevada, GVB Biopharma sets the standard for product quality. From using rigorous research, to testing the genetic stability of seeds, to verifying the cannabinoid capacity of its plants and purity of the distilled oil, the integrity of the GVB Biopharma process is reflected in every product.
SOURCE GVB Biopharma
Related Links
www.gvbbiopharma.com
Filed Under: Business
0 Comments
Latest on nvtip.com
- The Citizens Commission on Human Rights Annual Purple Heart Day Event will be Hosted at the Historic Fort Harrison
- Blake Harris the Leading Authority in International Asset Protection Joins Tom Hegna on "Financial Freedom with Tom Hegna"
- Psychedelics for Vets? CCHR Cites History of Exploitation and Failed Science
- GreenPal Empowers Lawn Care Pros Leveraging AI, Surpasses 5 Million Transactions
- Santa Monica Businesses Push Back on Bus Stop Relocation That Threatens Access and Safety
- Rachel Farris, CPA, Attends AICPA ENGAGE Conference and Participates in Thought Leader Symposium
- The Blue Luna Encourages Local Schools to Take Steps to Enhance Safety for Students and Staff
- The Sessions Studios Secures $300 Million Commitment to Launch World-Class Studio and 15-Film Global Slate
- Smart Resnse Unveils Smart Resnse(SRMS) Token-Powered AI Orchestration Platform to Revolutionize Multi-Billion Dollar Market
- Josh and Heidi Follow Up the Much Anticipated and Successful Launch of the "Spreading the Good BUZZ" Podcast with a Personal Request
- Travel Trailblazers: Top Global Finalists Shortlisted for Trip.com Group's Tourism Innovation Awards
- Revolutionary Blockchain Platform Okh Finance Announces Okh Finance(OKKH) Token Launch to Transform Global Asset Leasing Market
- Cover Girl Finalist Teisha Mechetti Questions Legitimacy of Inked Originals Competition, Demands Transparency
- Easton & Easton, LLP Files Suit Against The Dwelling Place Anaheim & Vineyard USA Over Abuse Allegations
- AI Visibility: The Key to Beating Google's AI Overviews and Regaining Traffic
- Stuck Doing Math or Figuring Out Life's Numbers? Calculator.now Makes It Stupidly Simple
- Colbert Packaging Announces WBENC Recognition
- DivX Empowers Media Enthusiasts with Free Expert Guides for Advanced MP4 Management
- Akon City Cancelled: Primal Mogul Confirms Senegal Scraps $6B Smart City Plan for $1.2B Resort
- Assent Expands Executive Team to Accelerate Global Growth & Innovation